Blue Earth Diagnostics, a Bracco company, is highlighting findings from the phase III Spotlight study regarding its Posluma (flotufolastat F-18) injection for prostate cancer. The results were published recently in Advances in Radiation Oncology.
The study assessed the use of FDA-approved Posluma in patients with recurrent prostate cancer, specifically its efficacy for African American men.
The study found that 93% of the African American cohort had a positive Posluma scan, consistent with the 87% detection rate for all other patients in the study. African American men accounted for 17% of the total study population.
Posluma is approved in the U.S. for PET imaging of prostate specific membrane antigen-positive lesions in men with prostate cancer. These patients also have suspected metastases and are candidates for initial definitive therapy or with suspected recurrence based on elevated serum prostate-specific antigen levels.
%20mol%20oct.0h6Wt2LMeF.png?crop=focalpoint&fit=crop&fp-x=0.5&fp-y=0.5&h=100&w=100&auto=format%2Ccompress&q=70)
%20mol%20oct.0h6Wt2LMeF.png?crop=focalpoint&fit=crop&fp-x=0.5&fp-y=0.5&h=167&w=250&auto=format%2Ccompress&q=70)
